Nanobiotix S.A. (NASDAQ:NBTX - Get Free Report) shares rose 3.6% on Tuesday . The stock traded as high as $4.36 and last traded at $4.36. Approximately 10,235 shares were traded during mid-day trading, a decline of 42% from the average daily volume of 17,666 shares. The stock had previously closed at $4.21.
Wall Street Analysts Forecast Growth
Separately, Guggenheim began coverage on shares of Nanobiotix in a report on Wednesday, August 28th. They issued a "buy" rating and a $12.00 price target for the company.
Check Out Our Latest Analysis on Nanobiotix
Nanobiotix Stock Down 5.0 %
The company's fifty day moving average is $5.02 and its two-hundred day moving average is $5.43.
Nanobiotix Company Profile
(
Get Free Report)
Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.
Read More
Before you consider Nanobiotix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nanobiotix wasn't on the list.
While Nanobiotix currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
